Medicamentos para prevenir las cefaleas migrañosas en ... - marchioli
Medicamentos para prevenir las cefaleas migrañosas en ... - marchioli
Medicamentos para prevenir las cefaleas migrañosas en ... - marchioli
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
ÍNDICE DE MATERIAS<br />
02 Ev<strong>en</strong>tos adversos que provocan retirada...............................................................................................39<br />
06 pizotif<strong>en</strong>o versus placebo...............................................................................................................................39<br />
01 Ev<strong>en</strong>tos adversos...................................................................................................................................39<br />
07 Trazodona vs. placebo...................................................................................................................................39<br />
01 Frecu<strong>en</strong>cia..............................................................................................................................................39<br />
02 Duración.................................................................................................................................................40<br />
03 Ev<strong>en</strong>tos adversos...................................................................................................................................40<br />
08 L-5-hidroxitriptofano versus placebo..............................................................................................................40<br />
01 Frecu<strong>en</strong>cia..............................................................................................................................................40<br />
02 Índice de migraña...................................................................................................................................41<br />
03 Índice de migraña (mejoría > 70%)........................................................................................................41<br />
04 Ev<strong>en</strong>tos adversos...................................................................................................................................41<br />
09 Clonidina vs. placebo.....................................................................................................................................41<br />
01 Frecu<strong>en</strong>cia (sin ataques)........................................................................................................................41<br />
02 Duración (< 4 horas)...............................................................................................................................42<br />
03 Int<strong>en</strong>sidad (leve).....................................................................................................................................42<br />
04 Ev<strong>en</strong>tos adversos...................................................................................................................................42<br />
10 Metoclopramida vs. placebo..........................................................................................................................43<br />
01 Índice de efectividad terapéutica (mejoría >70%)..................................................................................43<br />
11 Domperidona vs. placebo..............................................................................................................................43<br />
01 Índice de efectividad terapéutica (mejoría >70%)..................................................................................43<br />
12 Flunarizina versus ácido acetilsalicílico.........................................................................................................43<br />
01 Frecu<strong>en</strong>cia (reducción de 50% o más)...................................................................................................43<br />
02 Ev<strong>en</strong>tos adversos...................................................................................................................................44<br />
13 Flunarizina vs. nimodipina.............................................................................................................................44<br />
01 Frecu<strong>en</strong>cia (reducción > 50%)................................................................................................................44<br />
02 Ev<strong>en</strong>tos adversos...................................................................................................................................44<br />
14 Flunarizina vs. propranolol.............................................................................................................................45<br />
01 Frecu<strong>en</strong>cia (reducción > 75%)................................................................................................................45<br />
02 Ev<strong>en</strong>tos adversos...................................................................................................................................45<br />
15 Flunarizina versus dehidroergotamina...........................................................................................................45<br />
01 Frecu<strong>en</strong>cia..............................................................................................................................................45<br />
02 Duración.................................................................................................................................................46<br />
03 Int<strong>en</strong>sidad...............................................................................................................................................46<br />
04 Ev<strong>en</strong>tos adversos...................................................................................................................................46<br />
16 Metoclopramida vs. domperidona..................................................................................................................46<br />
01 Índice de efectividad terapéutica (mejoría >70%)..................................................................................46<br />
17 L-5-hidroxitriptofano versus pizotif<strong>en</strong>o...........................................................................................................47<br />
01 Índice de <strong>cefaleas</strong>...................................................................................................................................47<br />
02 Índice total de dolor................................................................................................................................47<br />
03 Ev<strong>en</strong>tos adversos...................................................................................................................................47<br />
ii<br />
<strong>Medicam<strong>en</strong>tos</strong> <strong>para</strong> <strong>prev<strong>en</strong>ir</strong> <strong>las</strong> <strong>cefaleas</strong> migrañosas <strong>en</strong> los niños<br />
Copyright © John Wiley & Sons Ltd. Usado con permiso de John Wiley & Sons, Ltd.